A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced kidney cancers prior to partial kidney removal and reconstruction, according to research published in the April online edition of BJU International.
A case of leptomeningeal carcinomatosis in a patient with known brain and lung metastases from renal cell cancer without previous systemic therapy is presented.
Multiple epidemiologic studies have linked the development of renal cancer to obesity. In this chapter, we begin with a review of selected population studies, followed by recent mechanistic discoveries that further link lipid deregulation to the RCC development.
A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced kidney cancers prior to partial kidney removal and reconstruction.
This unique and potentially life-threatening toxicity, along with the sequential single-agent activity of these agents in RCC, precludes further development or use of this combination in RCC when administered in this fashion.
Its been a long time coming, said James McClarnon, father of Sarah Sari McClarnon, who died in 2005 at age 11. Its a wonderful tribute and its what she liked. I just pray the school stays open.
yclooxygenase-2 (COX-2) is a key enzyme involved in the production of prostaglandins and its inhibitors have been shown to induce apoptosis in a variety of cancer cells.
Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma
We have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene , is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available. We here investigated whether angptl4 mRNA 1) could be a useful diagnostic and/or prognostic marker of ccRCC . . .
For this study, the NCI's Surgery Branch Chief, Dr. Steven A. Rosenberg, will lead a Phase II clinical trial investigating the combination of TenX Biopharma's zanolimumab, an investigational anti-CD4 therapeutic antibody, with aldesleukin (IL-2) for the treatment of metastatic melanoma and renal cell carcinoma.
. . . similar to Provenge in that it is personalized and uses dendritic cells. But CEO Abbey said that Argos has built on Dendreon's approach by using only dendritic cells rather than an antigen-presenting cell mixture.
|NeonCRM by Neon One|